ArticleInternational journal of clinical and experimental pathology2014
Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Systemic deuteration of SCID mice using the water-isotopologue deuterium oxide (DMolecular carcinogenesis · 2023Article
- MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.The Journal of experimental medicine · 2023Article
- Target c-Myc to treat pancreatic cancer.Cancer biology & therapy · 2022Article
- The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma.Frontiers in oncology · 2022Review
- The Potential Role of Changes in the Glucose and Lipid Metabolic Pathways in Gastrointestinal Cancer Progression: Strategy in Cancer Therapy.Gastrointestinal tumors · 2021Review
- Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells.Frontiers in pharmacology · 2020Article
- Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Tumor microenvironment participates in metastasis of pancreatic cancer.Molecular cancer · 2018Review
- Expression of uc.189 and its clinicopathologic significance in gynecological cancers.Oncotarget · 2018Article
- JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.Molecular cancer therapeutics · 2018Article
- HAT1 induces lung cancer cell apoptosis via up regulating Fas.Oncotarget · 2017Article
- Bioinformatics analysis of transcription profiling of solid pseudopapillary neoplasm of the pancreas.Molecular medicine reports · 2017Article
- Fas expression is downregulated in gastric cancer.Molecular medicine reports · 2017Article
- Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.Neoplasia (New York, N.Y.) · 2016Article
- High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer.Journal of cancer research and clinical oncology · 2016Article
- Expression and prognostic value of miR-92a in patients with gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer.Oncotarget · 2016Article
- Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value.Oncotarget · 2016Article
- Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer.Therapeutics and clinical risk management · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of molecular prognostic markers for pancreatic cancer patients could provide insightful information for their management in the clinic. The aim of the study is to investigate whether or not the expressions of c-Myc and Fas (CD95/APO1) have prognostic relevance for overall survival (OS) in patients with pancreatic cancer. we used immunohistochemistry on tissue microarrays containing 162 pancreatic cancer specimens to assess the protein expression levels of c-Myc and Fas. Kaplan-Meier survival analysis demonstrated that high level of c-Myc cytoplasmic expression was significantly correlated with worse survival in patients with pancreatic cancer (P = 0.012), while high level of Fas cytoplasmic expression was significantly associated with better outcome of pancreatic cancer (P = 0.046). However, multivariate Cox model analysis showed that tumor differentiation, lymph node status and c-Myc cytoplasmic expression were significant independent prognostic factors for OS (P < 0.001, P = 0.023, P = 0.001, respectively). On the contrary, Fas cytoplasmic expression did not independently influence patient's prognosis (P = 0.249). Our data suggested that high level of c-Myc cytoplasmic expression may be considered as a valuable marker for prognosis of pancreatic cancer.
Indexed as
Identifiers
24551298PMC3925922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.